Division of Nephrology, Department of Medicine, Loma Linda VA Health Care System, Loma Linda, CA, 92357, USA.
Department of Medicine, Loma Linda University School of Medicine, Loma Linda, CA, 92357, USA.
J Gen Intern Med. 2023 Jun;38(8):1911-1919. doi: 10.1007/s11606-023-08184-6. Epub 2023 Apr 12.
Coronavirus disease 2019 (COVID-19) was associated with severe acute illness including multiple organ failure. Acute kidney injury (AKI) was a common finding, often requiring dialysis support.
Define the incidence of new clinically identified chronic kidney disease (CKD) among patients with COVID-19 and no pre-existing kidney disease.
The South Carolina (SC) Department of Health and Environmental Control (DHEC) COVID-19 mandatory reporting registry of SC residents testing for COVID-19 between March 2020 and October 2021 was included.
The primary outcome was a new incidence of a CKD diagnosis (N18.x) in those without a pre-existing diagnosis of CKD during the follow-up period of March 2020 to January 14, 2022. Patients were stratified by severity of illness (hospitalized or not, intensive care unit needed or not). The new incidence of CKD diagnosis was examined using logistic regression and cox proportional hazards analyses.
Among patients with COVID-19 (N = 683,958) without a pre-existing CKD diagnosis, 8322 (1.2 %) were found to have a new diagnosis of CKD. The strongest predictors for subsequent CKD diagnosis were age ≥ 60 years hazard ratio (HR) 31.5 (95% confidence interval [95%CI] 25.5-38.8), and intervening (between COVID-19 and CKD diagnoses) AKI diagnosis HR 20.7 (95%CI 19.7-21.7). The presence of AKI was associated with an HR of 23.6, 95% CI 22.3-25.0, among those not hospitalized, and HR of 6.2, 95% CI 5.7-6.8 among those hospitalized, for subsequent CKD. COVID-19 was not significantly associated with subsequent CKD after accounting for the severity of illness and comorbidities.
Among SC residents, COVID-19 was not associated with CKD independent from indicators of the severity of illness, especially AKI diagnosis. Kidney-specific follow-up testing may be reserved for those high-risk for CKD development. Further prospective registries should examine the long-term kidney consequences to confirm these findings.
2019 年冠状病毒病(COVID-19)与包括多器官衰竭在内的严重急性疾病有关。急性肾损伤(AKI)是一种常见的表现,常需要透析支持。
确定 COVID-19 患者中无预先存在肾脏疾病的新发临床确诊慢性肾脏病(CKD)的发生率。
纳入了南卡罗来纳州(SC)卫生与环境控制部(DHEC)COVID-19 强制性报告登记处的 SC 居民 COVID-19 检测结果,检测时间为 2020 年 3 月至 2021 年 10 月。
主要结局是在 2020 年 3 月至 2022 年 1 月 14 日的随访期间,无预先诊断为 CKD 的患者中新发 CKD 诊断(N18.x)的发生率。根据疾病严重程度(住院或不住院,是否需要重症监护)对患者进行分层。使用逻辑回归和 Cox 比例风险分析检查 CKD 诊断的新发发生率。
在无预先诊断为 CKD 的 COVID-19 患者(N=683958 例)中,有 8322 例(1.2%)被诊断为新发 CKD。随后发生 CKD 诊断的最强预测因素是年龄≥60 岁(风险比 [HR] 31.5[95%置信区间[95%CI]25.5-38.8])和(COVID-19 和 CKD 诊断之间的)干预性 AKI 诊断(HR 20.7[95%CI 19.7-21.7])。在未住院的患者中,AKI 的存在与随后 CKD 的 HR 为 23.6,95%CI 为 22.3-25.0,而在住院患者中,HR 为 6.2,95%CI 为 5.7-6.8。在考虑到疾病严重程度和合并症后,COVID-19 与随后发生的 CKD 无显著相关性。
在南卡罗来纳州居民中,COVID-19 与 CKD 无关联,与疾病严重程度的指标无关,尤其是 AKI 诊断。可能需要对发生 CKD 风险较高的患者进行肾脏特异性随访检查。应进一步开展前瞻性登记研究以确认这些发现。